Market Overview

UPDATE: Stifel Terminates Coverage on Corcept Therapeutics Due to Reallocation of Resources

Share:
Related CORT
Mid-Morning Market Update: Markets Edge Lower; Cal-Maine Misses Q2 Expectations
Mid-Day Market Update: Dow Dips Over 1%; Harley-Davidson Shares Rise On Earnings Beat
Promising Pre-Clinical and Phase – Data Support Advance of Selective Cortisol Modulator ... (GuruFocus)

In a report published Monday, Stifel analyst Annabel Samimy terminated coverage on Corcept Therapeutics (NASDAQ: CORT).

In the report, Stifel noted, “Due to a reallocation of resources, we are discontinuing coverage of Corcept Therapeutics. Our last rating was Hold. Our last net loss estimates were ($0.53) for FY 2014, ($0.38) for 2015, breakeven for FY2016, $0.40 for FY2017, and $1.12 for FY 2018. However, these estimates should not be used as an indicator for the company going forward.”

Corcept Therapeutics closed on Friday at $4.08.

Latest Ratings for CORT

DateFirmActionFromTo
Dec 2015Janney CapitalInitiates Coverage onBuy
Apr 2015FBR CapitalInitiates Coverage onOutperform
Mar 2015Piper JaffrayUpgradesNeutralOverweight

View More Analyst Ratings for CORT
View the Latest Analyst Ratings

Posted-In: Annabel Samimy StifelAnalyst Color Termination Analyst Ratings

 

Related Articles (CORT)

View Comments and Join the Discussion!